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Prostatic disease causes enormous morbidity worldwide. Currently 
adenocarcinoma of the prostate (ACP) is the most common form 
of cancer in men in the USA, with a predicted cost of US $8.8 
billion for continuing care of these patients by 2020.1 Moreover, 
benign prostatic hyperplasia (BPH) affects an estimated 70% of 
men aged 61 - 70 years and 90% of those aged 81 - 90. By 2025, 
BPH is likely to affect 20% of the total male population.2 Improved 
understanding of these diseases could have a significant impact on 
male health.
ACP and BPH are chronic diseases with a long period 
of development and progression. Interestingly, a self-reported 
history of prostatitis is associated with ACP and BPH.3 The role 
of inflammation in prostatic disease is currently yet to be fully 
elucidated, although there is emerging evidence that prostatic 
inflammation may contribute to prostate growth in terms of 
hyperplastic or neoplastic changes.4 Histological evidence of 
inflammation has been reported in approximately 40% of cases 
of BPH and is associated with a significantly increased risk of 
acute urinary retention.5 About 20% of all human cancers are 
caused by chronic inflammation, perhaps including ACP.6 A better 
understanding of the relationship between prostatic inflammation 
and BPH or ACP may provide an opportunity to influence the 
diagnosis or treatment of prostatic disease. 
In a previous study, we analysed 405 men presenting with 
urinary retention and found histological evidence of prostatitis 
in 98/204 men (48.0%) with BPH and in 51/201 (25.4%) with 
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Objective. To determine the prevalence of prostatitis on histopathological evaluation of prostatic tissue in men without urinary retention. 
Design, setting and subjects. The clinical data and histopathology reports of men seen from January 1999 through March 2009 at our 
institution were analysed using Student’s t-test, the Mann-Whitney test and Fisher’s exact test where appropriate. Values were expressed as 
means, medians and ranges (p<0.05 accepted as statistically significant).
Outcome measures. Data collected included patient age, duration of lower urinary tract symptoms and hospitalisation, findings on digital 
rectal examination, prostate volume, haemoglobin concentration, serum creatinine and prostate-specific antigen (PSA) levels, and histological 
findings. 
Results. Prostatic tissue of 385 men without urinary retention at presentation was obtained via biopsy (48.3% of cases), transurethral 
prostatectomy (62.9%), retropubic prostatectomy (6.8%) or radical prostatectomy (28.3%). On histological examination, benign prostatic 
hyperplasia (BPH) was found to be present in 213 patients (55.3%) and adenocarcinoma of the prostate (ACP) in 172 (44.7%). Histological 
prostatitis was present in 130 patients (61.0%) with BPH and 51 (29.7%) with ACP (p<0.001). A previous study of 405 men presenting with 
urinary retention at our institution showed histological prostatitis in 98/204 (48.0%) with BPH and in 51/201 (25.4%) with ACP. The group of 
men with BPH alone had a significantly lower mean serum PSA at presentation (4.5 ng/ml, range 0.3 - 20.8 ng/ml) compared with the group 
with BPH and prostatitis (11.2 ng/ml, range 0.2 - 145 ng/ml, p=0.011). The mean PSA level at presentation did not differ significantly between 
the group with ACP only (40.9 ng/ml, range 0 - 255 ng/ml) and the group with ACP plus prostatitis (1 672 ng/ml, range 0.3 - 38 169 ng/ml, 
p=0.076). 
Conclusions. Among men presenting without urinary retention, histological prostatitis was significantly more prevalent in those with BPH 
than in those with ACP (61% v. 30%), similar to the previous study of men presenting with retention at our institution, in which histological 
prostatitis was significantly more prevalent in BPH than in ACP (48% v. 25%). This finding suggests that histological prostatitis is not 
significantly associated with the causation of ACP or urinary retention. Serum PSA at presentation was significantly higher in the group with 
BPH plus prostatitis compared with BPH alone, but not in the group with ACP plus prostatitis compared with ACP alone.
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ACP, suggesting that histological prostatitis is not significantly 
associated with causation of ACP in patients presenting with 
urinary retention.7 
The aims of this study were to determine the prevalence of 
prostatic inflammation in men with histologically proven BPH 
or ACP without urinary retention and to compare their clinical 
features.
Patients and methods
We performed a retrospective analysis of the clinical data on 
patients without urinary retention who underwent prostatic 
biopsy or prostatectomy between January 1999 and March 2009 
in the Urology Department of our institution, a tertiary-level 
academic teaching hospital. The results of special investigations 
were obtained from the Chemical Pathology, Microbiology and 
Radiology departments. Histopathology reports on prostatic 
tissue specimens obtained by transrectal biopsy, transurethral 
prostatectomy, or open prostatectomy were provided by the 
Department of Anatomical Pathology at our institution. 
The data were entered on an Excel database for statistical 
analysis with Student’s t-test, the Mann-Whitney test and Fisher’s 
exact test where appropriate, using GraphPad InStat software. All 
values are expressed as means or medians (ranges). A two-tailed 
p-value <0.05 was accepted as statistically significant.
Results
Prostatic tissue was examined in a total of 385 men who did not 
have urinary retention at presentation (mean age 67.2 years, 
median 67.1 years, range 47.4 - 97.0 years). Tissue was obtained 
by biopsy of the prostate in 48.3%, transurethral prostatectomy in 
62.9%, retropubic prostatectomy in 6.8% and radical prostatectomy 
in 28.3% (more than one procedure was performed in some 
patients). On microscopic examination BPH was present in 213 
patients (55.3%) and ACP in 172 (44.7%). Histological prostatitis 
was recorded by the pathologist in 130 of 213 men with BPH 
(61.0%) and in 51 of 172 (29.7%) of those with ACP (p<0.001). 
Compared with the group with ACP, the men with BPH had 
a statistically significantly higher mean serum prostate-specific 
antigen (PSA) level at presentation and a greater proportion 
of them had a clinically benign prostate on digital rectal 
examination (DRE) (Table 1). However, there were no significant 
differences regarding age, duration of lower urinary tract 
symptoms (LUTS), length of hospitalisation, prostate volume, 
haemoglobin concentration or creatinine level (Table 1).
The group of men with BPH alone had a significantly lower 
mean serum PSA level at presentation compared with the group 
with BPH and histological prostatitis. The groups were otherwise 
statistically equivalent (Table 2). 
Similarly, the group of men with ACP alone was statistically 
equivalent when compared with the group with ACP and 
histological prostatitis (Table 3).
Discussion
There is emerging evidence suggesting a role of intraprostatic 
inf lammation in prostatic disease, although its precise 
role in the pathogenesis or progression of disease has yet 
Table 1. Comparison of men with histological benign prostatic hyperplasia v. adenocarcinoma of the prostate
  BPH ACP p-value
Number, N 213 172
Age (years), mean (range) 67.6 (48.9 - 97.0) 66.7 (47.4 - 83.4) 0.4614
Histological prostatitis, n (%) 130/213 (61.0) 51/172 (29.7) <0.001
LUTS duration (months), mean (range) 27.1 (0.5 - 180.0) 15.8 (1.0 - 60.0) 0.5397
DRE: BPH, n (%) 92/98 (93.9) 40/77 (51.9) <0.0001
Hospitalisation (d), mean (range) 7.7 (1.0 - 38.0) 10.3 (2.0 - 181.0) 0.1228
Prostate volume (ml), mean (range) 45.6 (5.0 - 174.0) 46.1 (15.0 - 190.0) 0.9308
Haemoglobin (g/dl), mean (range) 13.6 (4.50 - 17.1) 13.6 (9.00 - 17.0) 0.9738
Creatinine (μmol/l), mean (range) 156.6 (10.0 - 1 636.0) 123.9 (72.0 - 834.0) 0.6946
PSA (ng/ml), mean (median; range) 8.8 (3.5; 0.2 - 145.0) 504.1 (10.4; 0 - 38 169) <0.0001
Table 2. Comparison of men with histological benign prostatic hyperplasia only v. BPH plus prostatitis
  BPH only BPH + prostatitis p-value
Number, N 83 130
Age (years), mean (range) 66.5 (48.9 - 88.3) 68.2 (51.1 - 97.0) 0.1855
Prostate volume (ml), mean (range) 39.4 (20.0 - 100.0) 49.7 (5.0 - 174.0) 0.5245
Haemoglobin (g/dl), mean (range) 14.0 (10.0 - 17.1) 13.4 (4.5 - 16.9) 0.0860
Creatinine (μmol/l), mean (range) 141.6 (10.0 - 1 265.0) 166.6 (32.0 - 1 636.0) 0.5386
PSA (ng/ml), mean (median; range) 4.5 (3.0; 0.3 - 20.8) 11.2 (6.0; 0.2 - 145.0) 0.0105
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to be determined. Dennis et al. conducted a meta-analysis 
examining the reported associations between prostatitis and 
ACP and found an increased risk of ACP among men with a 
history of prostatitis (odds ratio 1.7, 95% confidence interval 
1.3 - 2.1).8 
There are several potential causes of prostatic inflammation, 
including, though not limited to, infectious agents, hormonal 
changes, physical trauma, urine reflux and dietary habits.6 
Molecular pathological studies have suggested that inflammation 
generates free radicals, which cause severe oxidative and 
nitrosative damage to DNA and prostatic epithelial cells as well 
as inducing permanent genomic alterations, which may result in 
carcinogenesis.4,8
Moreover, genetic studies suggest that repeated bouts of 
injury – possibly due to damage from inflammatory cells – 
cause focal atrophy or proliferative inflammatory atrophy, 
leading to an increase in proliferation.6,9,10 A  small subset of the 
resultant cells may contain somatic genome alterations such as 
cytosine methylation within GSTP1 and telomere shortening, 
creating an increase in genetic instability that might initiate 
high-grade prostatic intraepithelial neoplasia and early ACP. 
Further insults activate further oncogenic transcription factors 
and deactivate tumour-suppressor genes, driving tumour 
progression.
Considering this evidence, our study sought to evaluate the 
prevalence of histological inflammation in men with ACP. A 
previous study of 405 men presenting with urinary retention 
found histological evidence of prostatitis in 48% of men with 
BPH and 25% with ACP (p<0.0001).7 Data from the current 
study are similar; among 385 men who did not have urinary 
retention at presentation, 61% of those with BPH and 30% of 
those with ACP were found to have histological evidence of 
prostatitis (p<0.001). This suggests that histological prostatitis 
is more significantly associated with the causation of BPH 
than with that of ACP. Of note, other groups have also failed 
to demonstrate compelling evidence for a role of chronic 
inflammation with ACP.11,12 
Regarding BPH, Mishra et al. found an increased incidence 
of acute and/or chronic intraprostatic inflammation (ACI) 
in more advanced BPH by utilising urinary retention as an 
endpoint in the natural history of BPH.2 Asgari et al. also 
demonstrated a significant association between ACI and 
acute urinary retention.13 Importantly, the MTOPS study 
demonstrated that men with BPH and prostatic inflammation 
showed an increased percentage of disease progression. At 
4-year follow-up, only BPH patients with inflammation 
developed acute urinary retention.14 In the present study, 
prostatitis was present histologically in 61% of men with 
BPH. While this finding corresponds to the hypothesis that 
inflammation and BPH may be related, this study does not 
address BPH progression.
Several studies have evaluated the effect of inflammation and 
BPH on serum PSA levels. Irani et al. analysed 66 patients with 
exclusively benign prostatic tissue on prostate biopsies and found 
a significant correlation between the aggressiveness grading of the 
inflammatory reaction and serum PSA.15 Nadler et al. found that 
acute and chronic inflammation was significantly more prevalent 
in patients with an elevated serum PSA level (>4.0 ng/ml) (63% v. 
27% and 99% v. 77%, respectively).16 Recently a prospective study 
of 51 patients without evidence of ACP demonstrated extension 
of the inflammatory process directly related to elevations of serum 
PSA levels.17 Correlating with these conclusions, the present data 
demonstrate a significantly elevated serum PSA in men with BPH 
plus prostatitis versus BPH alone (504.1 v. 8.8 ng/ml, p>0.001). 
Approaching significance, serum PSA was also increased in men 
with ACP plus prostatitis versus ACP alone (1 672 v. 41 ng/ml, 
p=0.076).
The limitations of this study include the facts that it was 
retrospective and some study parameters were incompletely 
recorded. Histological examination of prostatic tissue was 
not performed by a single pathologist, and data analysis was 
based on the written reports of various pathologists, so there 
may be under-reporting of inflammatory changes. Also, the 
extent or grade of inflammation was not quantified. However, 
there is no reason to suspect that the assessment of histological 
prostatitis would be biased by the presence of underlying BPH 
or ACP. Only men who had undergone procedures providing 
prostatic tissue were included in this study, so those with less 
severe prostatic disease may have been excluded. Finally, the 
study may be underpowered to demonstrate significance in all 
variables, such as PSA in the ACP versus ACP plus prostatitis 
cohorts.
While accumulating experimental evidence suggests a role 
for inflammation in both BPH progression and the causation 
of ACP, our clinical data do not entirely support this. Further 
clinical studies are needed to develop a more comprehensive 
understanding of the relationship between inflammation and 
prostatic disease. 
Conclusion
In men without urinary retention, histological prostatitis was 
significantly more prevalent in those with BPH than ACP. Serum 
Table 3. Comparison of men with histological adenocarcinoma of the prostate only v. ACP plus prostatitis
ACP only ACP plus prostatitis p-value
Number, N 121 51
Age (years), mean (range) 67.2 (52.8 - 82.9) 65.4 (47.4 - 83.4) 0.3517
Prostate volume (ml), mean (range) 46.3 (15.0 - 190.0) 45.8 (20.0 - 86.0) 0.9685
Haemoglobin (g/dl), mean (range) 13.5 (9.0 - 17.0) 13.9 (11.5 - 17.0) 0.3615
Creatinine (μmol/l), mean (range) 130.0 (72.0 - 834.0) 106.8 (81.0 - 183.0) 0.3371
PSA (ng/ml), mean (median; range) 40.9 (13.2; 0 - 255.0) 1 672 (9.1; 0.3 - 38 169) 0.0759
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PSA at presentation was significantly higher in the group with 
BPH plus prostatitis than in the group with BPH alone, and 
approached significance in the group with ACP plus prostatitis 
compared with the group with ACP alone. The results of this study 
suggest that histological prostatitis is not significantly associated 
with the causation of ACP or with urinary retention.
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